dTAGV-1 represents a degrader designed to target fusion proteins involving mutant FKBP12F36V. It consists of a ligand specifically tailored for the F36V single-point mutated FKBP12, a linker, and a ligand binding to von Hippel-Lindau (VHL). This compound effectively induces robust and selective degradation of FKBP12F36V fusion proteins, demonstrating its efficacy both in vitro and in vivo.
Usually ships within 24 hours.